The estimated Net Worth of Jeffrey Paley is at least $477 Thousand dollars as of 3 December 2018. Jeffrey Paley owns over 15,000 units of Avenue Therapeutics Inc stock worth over $231,023 and over the last 11 years Jeffrey sold ATXI stock worth over $245,600.
Sign up
Jeffrey Paley ATXI stock SEC Form 4 insiders trading
Jeffrey has made over 2 trades of the Avenue Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Jeffrey bought 15,000 units of ATXI stock worth $78,600 on 3 December 2018.
The largest trade Jeffrey's ever made was selling 20,000 units of Avenue Therapeutics Inc stock on 14 August 2014 worth over $245,600. On average, Jeffrey trades about 5,000 units every 225 days since 2013. As of 3 December 2018 Jeffrey still owns at least 79,663 units of Avenue Therapeutics Inc stock.
You can see the complete history of Jeffrey Paley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jeffrey Paley's mailing address?
Jeffrey's mailing address filed with the SEC is 2 Gansevoort St 9TH FLOOR, New York, NY 10014, USA.
Insiders trading at Avenue Therapeutics Inc
Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over $3,169,091 worth of Avenue Therapeutics Inc stock and bought 867,969 units worth $1,169,423 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss, and Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of $210,758. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth $86,380.
What does Avenue Therapeutics Inc do?
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
What does Avenue Therapeutics Inc's logo look like?
Complete history of Jeffrey Paley stock trades at Retrophin and Avenue Therapeutics Inc
Avenue Therapeutics Inc executives and stock owners
Avenue Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Lucy Lu,
President, Chief Executive Officer, Director -
Dr. Xiaoqin Lu M.D.,
Pres, CEO & Director -
Joseph Vazzano,
Chief Financial Officer, Principal Financial Officer and Corporate Secretary -
Joseph Walter Vazzano,
CFO, Principal Financial Officer & Company Sec. -
Neil Herskowitz,
Independent Director -
Jay Kranzler,
Independent Director -
Thomas Moore,
Independent Director -
Dr. Lindsay Allan Rosenwald,
Exec. Chairman -
Garrett Ingram,
Director -
Jaideep Gogtay,
Director -
Lindsay Rosenwald,
Executive Chairman of the Board -
Dr. Scott A. Reines M.D., Ph.D.,
Interim Chief Medical Officer -
Jeffrey Paley,
Director -
Akhtar Samad,
Director -
Scott Reines,
Interim Chief Medical Officer -
Michael S Weiss,
Director -
Curtis Gale Oltmans,
Director -
Pharmaceuticals, Inc. Inva Gen,
10% owner -
Robert L Davidow,
10% owner -
Biotech, Inc. Fortress,
10% owner -
David Jin,
Interim PFO and COO -
Faith L. Charles,
Director